Lenvatinib + Everolimus
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent and Refractory Solid Tumors
Conditions
Recurrent and Refractory Solid Tumors
Trial Timeline
Nov 16, 2017 → Sep 30, 2022
NCT ID
NCT03245151About Lenvatinib + Everolimus
Lenvatinib + Everolimus is a phase 1/2 stage product being developed by Eisai for Recurrent and Refractory Solid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT03245151. Target conditions include Recurrent and Refractory Solid Tumors.
What happened to similar drugs?
4 of 20 similar drugs in Recurrent and Refractory Solid Tumors were approved
Approved (4) Terminated (0) Active (16)
🔄Nivolumab + Gemcitabine + Cisplatin + Carboplatin + Paclitaxel + PemetrexedOno PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03324373 | Phase 1 | Completed |
| NCT03245151 | Phase 1/2 | Completed |
| NCT03173560 | Phase 2 | Completed |
| NCT02915783 | Phase 2 | Completed |
| NCT02454478 | Phase 1 | Completed |
| NCT01136733 | Phase 1/2 | Completed |
Competing Products
20 competing products in Recurrent and Refractory Solid Tumors